©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 6 Issue 2 Page 30-34 2025

https://doi.org/10.59298/NIJRMS/2025/6.2.3034

Balancing Safety and Efficacy in Neonatal Immunotherapy: Challenges and Future Directions

Omukisa Kireba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Neonatal immunotherapy is rapidly emerging as a transformative approach to reducing the high burden of infectious diseases and immune-mediated conditions in early life. Due to the immaturity of the neonatal immune system—characterized by reduced antigen presentation, lower cytokine production, and limited immunological memory—designing interventions that are both safe and effective poses unique challenges. This review provides a comprehensive analysis of current and emerging immunotherapeutic strategies tailored for neonates, including passive immunity through monoclonal antibodies and IVIG, next-generation vaccines utilizing mRNA and novel adjuvants, microbiota-based interventions to restore immune-microbial balance, and nanotechnology-enabled delivery systems for precise targeting. Special attention is given to the complexities of ensuring safety in this vulnerable population, including risks of immune overactivation, developmental interference, and ethical concerns in clinical research. Regulatory hurdles and the need for age-specific formulations further complicate clinical translation. Advances in systems biology and omics technologies are enabling personalized approaches to neonatal immunotherapy by identifying immune signatures and predictive biomarkers. Looking ahead, the integration of immunological insights, ethical frameworks, and technological innovations will be essential to optimize and implement effective neonatal immunotherapies. Future strategies must prioritize both individual patient needs and global equity to ensure that these innovations benefit all neonates, particularly those most at risk.

Keywords: Neonatal immunotherapy, Immune system immaturity, Next-generation vaccines, Microbiota-based interventions, Precision medicine

INTRODUCTION

Neonates, especially those born preterm or with underlying health conditions, are highly vulnerable to infections due to the functional immaturity of both their innate and adaptive immune systems [1] The neonatal immune response is characterized by diminished antigen presentation, reduced pro-inflammatory cytokine production, and a skewing toward regulatory and tolerogenic responses [2]. These features, while protective against harmful inflammation during fetal development, leave infants poorly equipped to combat pathogens in the early postnatal period. Consequently, infection-related morbidity and mortality remain significant contributors to neonatal intensive care admissions and adverse long-term outcomes, despite major advances in neonatal care and supportive therapies [3,4] In this context, immunotherapeutic interventions have emerged as promising tools to strengthen neonatal immune defenses and reduce infection-related complications [5] These interventions include passive immunization with monoclonal antibodies, the development of age-specific vaccines, modulation of the gut microbiota, and innovative delivery strategies such as nanotechnology-based systems [6] While the potential benefits are substantial, the delicate physiology and immune immaturity of neonates demand a cautious, evidence-based approach [7] Safety concerns, regulatory complexities, and ethical issues related to clinical trials in neonates further complicate the translation of immunotherapies into standard care [8] This review provides a comprehensive examination of current and emerging immunotherapeutic strategies in neonatology, with a focus on balancing safety and efficacy. It explores the mechanistic underpinnings of these approaches, assesses clinical progress, and highlights the challenges that remain. Additionally, it examines how emerging tools in systems biology and precision medicine

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

are helping to tailor interventions to the unique immunological profiles of neonates. Ultimately, this review aims to provide a roadmap for advancing neonatal immunotherapy in a way that is scientifically rigorous, ethically sound, and globally equitable, offering the potential to improve outcomes for the most vulnerable patient population.

Current Immunotherapeutic Strategies

Recent advancements in immunotherapy have led to the development of multiple strategies aimed at enhancing immune protection in neonates [9] These approaches are designed to complement or stimulate the underdeveloped neonatal immune system, providing both immediate and long-term defense against pathogens [10] Given the delicate physiological status of neonates, especially those born preterm, immunotherapeutic strategies must be tailored to ensure maximum efficacy with minimal risk.

Passive Immunotherapeutics

Passive immunization involves the administration of exogenous antibodies to provide immediate, short-term protection [11]. It bypasses the need for an active immune response, making it especially beneficial for neonates with immature immune systems. Monoclonal antibodies (mAbs) have proven particularly effective, with palivizumab and nirsevimab being used for the prevention of respiratory syncytial virus (RSV) infections—a major cause of lower respiratory tract illness in infants [12] Nirsevimab, a long-acting mAb, offers broader protection with fewer doses. Intravenous immunoglobulin (IVIG) therapy, derived from pooled donor plasma, is also employed in managing neonatal sepsis, immune deficiencies, and certain inflammatory disorders, although its use remains selective and based on clinical severity [13]

Next-Generation Vaccines

Conventional vaccines are often suboptimal in neonates due to immune immaturity [14]. To address this, next-generation vaccines are being developed to enhance both safety and immunogenicity. mRNA-based vaccines, proven successful in adult populations, are under evaluation for pediatric use. These offer rapid development timelines and strong immune activation, especially when formulated with lipid nanoparticles (LNPs) [15] Additionally, novel adjuvants—such as toll-like receptor (TLR) agonists—are being incorporated to improve innate immune activation [16]. Needle-free vaccines, including intranasal and oral formulations, are particularly attractive in neonates for stimulating mucosal immunity and enhancing compliance.

Microbiota-Based Interventions

The neonatal gut microbiome significantly influences immune development. Disruptions to microbial colonization, common in preterm or antibiotic-exposed infants, can impair immune function and increase infection risk [16]. Probiotics (Bifidobacterium and Lactobacillus species), prebiotics, and synbiotics have shown efficacy in preventing necrotizing enterocolitis (NEC) and sepsis. Fecal microbiota transplantation (FMT), though still experimental in neonates, offers a potential avenue for restoring microbial and immune homeostasis in severe dysbiosis [17, 18].

Nutritional Immunomodulators

Optimal nutrition supports immune resilience in neonates. Vitamins A, D, and zinc are essential for epithelial barrier maintenance and immune cell function. Omega-3 fatty acids possess anti-inflammatory properties, while human milk oligosaccharides (HMOs) in breast milk promote beneficial microbiota and pathogen defense [19].

Nanotechnology in Immunotherapy

Nanotechnology provides innovative tools for immunotherapeutic delivery. Lipid nanoparticles (LNPs) and polymeric carriers can encapsulate antigens, adjuvants, and bioactive molecules, allowing for targeted and sustained release [20]. These systems improve bioavailability and reduce systemic toxicity, making them particularly suited for neonatal applications.

Challenges in Balancing Safety and Efficacy

Developing immunotherapeutic interventions for neonates involves complex challenges due to the delicate balance between stimulating an effective immune response and maintaining safety [21]. The immature immune system, physiological vulnerability, and ethical considerations unique to this population demand highly cautious and individualized approaches.

Immune Immaturity

Neonates, particularly those born prematurely, possess an immune system that is functionally distinct from that of older children and adults [22]. Their immune responses are skewed toward tolerance to prevent excessive inflammation that could damage developing tissues [23] This immunological hypo-responsiveness results in a limited ability to mount effective responses to infections and vaccines. Therefore, immunotherapies must be specifically tailored to enhance protection without overwhelming or misdirecting the immune system. This challenge necessitates innovative strategies, such as adjuvants that mimic natural immune signals or delivery platforms that localize immune activation.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

Safety Concerns

Because neonates have immature metabolic and detoxification pathways, they are at heightened risk for adverse events from immunotherapeutic agents [24] Overactivation of the immune system may lead to hyperinflammatory responses, tissue damage, or the development of autoimmune phenomena. Preterm infants, with their fragile organ systems, are particularly susceptible. Rigorous safety assessments, including age-specific toxicology studies and long-term monitoring, are essential before clinical application [25].

Regulatory Barriers

The development and approval of pediatric and neonatal immunotherapies are often hindered by complex regulatory requirements [26] Clinical trials involving neonates are limited by strict ethical oversight, the need for extensive preclinical data, and challenges in designing age-appropriate formulations and dosing. These hurdles slow the translation of promising interventions from bench to bedside [27

Ethical Considerations

Neonates are among the most vulnerable populations in medical research. Informed consent must be obtained from parents or guardians, often during emotionally stressful periods [28]. Additionally, trial designs must minimize risk while offering potential benefit. Balancing innovation with protection requires adherence to robust ethical frameworks and transparent communication with caregivers.

Role of Systems Biology and Precision Immunotherapy

The integration of systems biology into neonatal immunotherapy is revolutionizing our understanding of the neonatal immune system and paving the way for precision medicine approaches [29] Omics technologies—including transcriptomics, proteomics, metabolomics, and epigenomics—allow researchers to capture comprehensive molecular snapshots of neonatal immune responses at various stages of development and during disease states [30] These high-dimensional datasets can reveal specific immune signatures associated with infection susceptibility, vaccine responsiveness, or adverse immunologic reactions. When combined with advanced computational tools such as artificial intelligence (AI) and machine learning, these data can be analyzed to identify predictive biomarkers, uncover disease pathways, and model immune responses to various interventions [31] For example, transcriptomic profiling has been used to differentiate neonates at high risk for sepsis, while proteomic analyses have uncovered potential markers for immune dysregulation in preterm infants. This systems-level insight enables the development of personalized immunotherapeutic strategies tailored to an individual neonate's immune profile [31] Such precision approaches may include selecting optimal vaccine formulations, adjusting dosages of immunomodulators, or timing interventions to coincide with developmental windows of immune responsiveness. Ultimately, systems biology not only enhances our mechanistic understanding but also holds the promise of improving safety, efficacy, and equity in neonatal immunotherapy by aligning treatments with the specific needs of each infant.

Future Directions

The future of neonatal immunotherapy lies in designing interventions that are not only effective and safe but also ethically sound and globally accessible [32]. A key priority is the development of age-specific vaccines that align with the distinct immunological landscape of neonates. This includes the use of novel adjuvants, such as toll-like receptor agonists, and advanced delivery systems like nanoparticles, which can enhance immunogenicity while minimizing reactogenicity [33]. Equally important is the integration of microbiome and nutritional data to create synergistic interventions. Understanding how gut microbiota and micronutrient status influence immune development can guide the design of personalized, multi-modal therapies, such as combining vaccines with probiotics or immunonutrients [34]. The expansion of ethical frameworks is critical to support responsible research in this vulnerable population. Ethical trial designs, transparent consent processes, and parental engagement are necessary to ensure the protection and inclusion of neonates in immunotherapy research [35]. Addressing global inequities is also essential. Many low- and middle-income countries bear the highest burden of neonatal infections yet face limited access to innovative therapies. Investment in infrastructure, capacity building, and equitable distribution models is needed to close this gap. Lastly, robust longitudinal safety monitoring, including registries and post-marketing surveillance, is vital to track long-term outcomes and guide clinical practice in real-world settings.

CONCLUSION

Achieving the delicate balance between safety and efficacy in neonatal immunotherapy demands a comprehensive, multidisciplinary approach that integrates insights from immunology, biotechnology, ethics, and global health. The evolving landscape of Immunotherapeutics —spanning next-generation vaccines, microbiota-based strategies, nanotechnology, and systems biology—offers transformative potential for protecting the most vulnerable patient population. However, realizing this potential requires sustained investment in basic and translational research, robust ethical oversight in clinical trials, and global initiatives to ensure equitable access to innovations. By aligning

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

scientific advancement with ethical responsibility and public health priorities, neonatal immunotherapy can become a cornerstone of safer, more effective early-life care worldwide.

REFERENCES

1. Sharma AA, Jen R, Butler A, Lavoie PM. The developing human preterm neonatal immune system: a case for more research in this area. Clin Immunol. 2012; 145(1):61-8. doi: 10.1016/j.clim.2012.08.006. Epub 2012 Aug 17. PMID: 22926079; PMCID: PMC4556448.
2. Collins A, Weitkamp JH, Wynn JL. Why are preterm newborns at increased risk of infection? Arch Dis Child Fetal Neonatal Ed. 2018; 103(4):F391-F394. doi: 10.1136/archdischild-2017-313595. Epub 2018 Jan 30. PMID: 29382648; PMCID: PMC6013388.
3. van Well, G.T.J., Daalderop, L.A., Wolfs, T. *et al.* Human perinatal immunity in physiological conditions and during infection. *Mol Cell Pediatr*., 2017; **4**, 4. https://doi.org/10.1186/s40348-017-0070-1
4. Fortmann MI, Dirks J, Goedicke-Fritz S, Liese J, Zemlin M, Morbach H, Härtel C. Immunization of preterm infants: current evidence and future strategies to individualized approaches. Semin Immunopathol. 2022; 44(6):767-784. doi: 10.1007/s00281-022-00957-1. Epub 2022 Aug 3. PMID: 35922638; PMCID: PMC9362650.
5. PrabhuDas, M., Adkins, B., Gans, H. *et al.* Challenges in infant immunity: implications for responses to infection and vaccines. *Nat Immunol*., 2011; **12**, 189–194. https://doi.org/10.1038/ni0311-189
6. Aslam, S., O'Hare, F., Eliwan, H., Molloy, E.J. Immunology and Immunodeficiencies in Children. In: Puri, P. (eds) Pediatric Surgery. Springer, Berlin, Heidelberg, 2019. https://doi.org/10.1007/978-3-642-38482-0_29-2
7. Newburg, D., Walker, W. Protection of the Neonate by the Innate Immune System of Developing Gut and of Human Milk. *Pediatr Res*., 2007; **61**, 2–8. https://doi.org/10.1203/01.pdr.0000250274.68571.18
8. Wolska M, Wypych TP, Rodríguez-Viso P. The Influence of Premature Birth on the Development of Pulmonary Diseases: Focus on the Microbiome. *Metabolites*. 2024; 14(7):382. https://doi.org/10.3390/metabo14070382
9. Singh A, Kaur H, Gupta G, et al. Enhancement of Immunity and Health in Neonates and Infants. Journal of Neonatology. 2021; 35(3):138-154. doi:10.1177/09732179211044332
10. Beltrami S, Rizzo S, Schiuma G, Speltri G, Di Luca D, Rizzo R, Bortolotti D. Gestational Viral Infections: Role of Host Immune System. *Microorganisms*. 2023; 11(7):1637. https://doi.org/10.3390/microorganisms11071637
11. Marcotte H, Hammarström L. Passive Immunization: Toward Magic Bullets. Mucosal Immunology. 2015:1403–34. doi: 10.1016/B978-0-12-415847-4.00071-9. Epub 2015 Mar 13. PMCID: PMC7150278.
12. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis. 2002; 8(8):833-41. doi: 10.3201/eid0808.010516. PMID: 12141970; PMCID: PMC3369592.
13. Marshall, J.S., Warrington, R., Watson, W. *et al.* An introduction to immunology and immunopathology. *Allergy Asthma Clin Immunol*., 2018; **14** (Suppl 2), 49. https://doi.org/10.1186/s13223-018-0278-1
14. Pires R, Rodrigues L, Santos FM, Duarte IF, Ciordia S, Peixe A, Cardoso H. Establishment of a Protocol for the Characterization of Secreted Biomolecules in Somatic Embryogenic Cultures of *Olea europaea* L. *Horticulturae*. 2025; 11(3):331. https://doi.org/10.3390/horticulturae11030331
15. Rodríguez-Fuentes G, Campo-Prieto P, Cancela-Carral JM. Immersive Virtual Reality as Physical and Cognitive Therapy in Acquired Brain Injury: TEVI-DCA Program. *Electronics*. 2025; 14(6):1204. https://doi.org/10.3390/electronics14061204
16. Yang JX, Tseng JC, Yu GY, Luo Y, Huang CF, Hong YR, Chuang TH. Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases. Pharmaceutics. 2022; 14(2):423. doi: 10.3390/pharmaceutics14020423. PMID: 35214155; PMCID: PMC8878135.
17. Sanidad KZ, Zeng MY. Neonatal gut microbiome and immunity. Curr Opin Microbiol. 2020; 56:30-37. doi: 10.1016/j.mib.2020.05.011. Epub 2020 Jul 4. PMID: 32634598; PMCID: PMC8729197.
18. Morreale C, Giaroni C, Baj A, Folgori L, Barcellini L, Dhami A, Agosti M, Bresesti I. Effects of Perinatal Antibiotic Exposure and Neonatal Gut Microbiota. Antibiotics (Basel). 2023; 12(2):258. doi: 10.3390/antibiotics12020258. PMID: 36830169; PMCID: PMC9951864.
19. Groer, M.W., Luciano, A.A., Dishaw, L.J. *et al.* Development of the preterm infant gut microbiome: a research priority. *Microbiome*., 2014; **2**, 38. https://doi.org/10.1186/2049-2618-2-38

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

20. Beharry KD, Latkowska M, Valencia AM, Allana A, Soto J, Cai CL, Golombek S, Hand I, Aranda JV. Factors Influencing Neonatal Gut Microbiome and Health with a Focus on Necrotizing Enterocolitis. *Microorganisms*. 2023; 11(10):2528. https://doi.org/10.3390/microorganisms11102528
21. Almawash S. Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy. *Cancers*. 2025; 17(5):880. https://doi.org/10.3390/cancers17050880
22. Muhammad, S., Fan, T., Hai, Y. *et al.* Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. *Mol Cancer.*, 2023; **22**, 121. https://doi.org/10.1186/s12943-023-01826-7
23. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017; 9(6):7204-7218. doi: 10.18632/oncotarget.23208. PMID: 29467962; PMCID: PMC5805548.
24. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1):121-41. doi: 10.1016/j.cell.2014.03.011. PMID: 24679531; PMCID: PMC4056765.
25. National Research Council (US) Committee on Pesticides in the Diets of Infants and Children. Pesticides in the Diets of Infants and Children. Washington (DC): National Academies Press (US); 1993. 3, Perinatal and Pediatric Toxicity. Available from: https://www.ncbi.nlm.nih.gov/books/NBK236272/
26. Ramel SE, Brown LD, Georgieff MK. The Impact of Neonatal Illness on Nutritional Requirements-One Size Does Not Fit All. Curr Pediatr Rep. 2014; 2(4):248-254. doi: 10.1007/s40124-014-0059-3. PMID: 25722954; PMCID: PMC4337785.
27. Pavelescu LA, Enache RM, Roşu OA, Profir M, Creţoiu SM, Gaspar BS. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors. *International Journal of Molecular Sciences*. 2024; 25(17):9659. https://doi.org/10.3390/ijms25179659
28. Institute of Medicine (US) Committee on Clinical Research Involving Children; Field MJ, Behrman RE, editors. Ethical Conduct of Clinical Research Involving Children. Washington (DC): National Academies Press (US); 2004. 5, Understanding and Agreeing to Children's Participation in Clinical Research. Available from: https://www.ncbi.nlm.nih.gov/books/NBK25560/
29. Morrow, B.M., Argent, A.C. & Kling, S. Informed consent in paediatric critical care research – a South African perspective. *BMC Med Ethics.*, 2015; **16**, 62. https://doi.org/10.1186/s12910-015-0052-6
30. Kaye, D.K. The ethical justification for inclusion of neonates in pragmatic randomized clinical trials for emergency newborn care. *BMC Pediatr.*, 2019; **19**, 218. https://doi.org/10.1186/s12887-019-1600-x
31. Manda-Taylor L, Liomba A, Taylor TE, Elwell K. Barriers and Facilitators to Obtaining Informed Consent in a Critical Care Pediatric Research Ward in Southern Malawi. Journal of Empirical Research on Human Research Ethics. 2019;14(2):152-168. doi:10.1177/1556264619830859
32. Sturrock S, Sadoo S, Nanyunja C, Le Doare K. Improving the Treatment of Neonatal Sepsis in Resource-Limited Settings: Gaps and Recommendations. Res Rep Trop Med. 2023; 14:121-134. doi: 10.2147/RRTM.S410785. PMID: 38116466; PMCID: PMC10728307.
33. Spirito F, Nocini R, Mori G, Albanese M, Georgakopoulou EA, Sivaramakrishnan G, Khalil B, Špiljak B, Surya V, Mishra D, et al. The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review. *International Journal of Molecular Sciences*. 2024; 25(23):12990. https://doi.org/10.3390/ijms252312990
34. Chehelgerdi M, Behdarvand Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M, Salmanizadeh S, Rashidi M, Niazmand A, Ahmadi S, Feizbakhshan S, Kabiri S, Vatandoost N, Ranjbarnejad T. Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy. Mol Cancer. 2023; 22(1):189. doi: 10.1186/s12943-023-01873-0. PMID: 38017433; PMCID: PMC10683363.
35. Deng D, Hao T, Lu L, Yang M, Zeng Z, Lovell JF, Liu Y, Jin H. Applications of Intravital Imaging in Cancer Immunotherapy. *Bioengineering*. 2024; 11(3):264. https://doi.org/10.3390/bioengineering11030264

CITE AS: Omukisa Kireba K. (2025). Balancing Safety and Efficacy in Neonatal Immunotherapy: Challenges and Future Directions. Newport International Journal of Research in Medical Sciences, 6(2):30-34 https://doi.org/10.59298/NIJRMS/2025/6.2.3034